iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/12665391/
The role of hormones and hormonal treatments in premenstrual syndrome - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003;17(5):325-42.
doi: 10.2165/00023210-200317050-00003.

The role of hormones and hormonal treatments in premenstrual syndrome

Torbjörn Bäckström  1 , Lotta Andreen, Vita Birzniece, Inger Björn, Inga-Maj Johansson, Maud Nordenstam-Haghjo, Sigrid Nyberg, Inger Sundström-Poromaa, Göran Wahlström, Mingde Wang, Di Zhu
Affiliations
Review

The role of hormones and hormonal treatments in premenstrual syndrome

Torbjörn Bäckström et al. CNS Drugs. 2003.

Abstract

Premenstrual syndrome (PMS) is a menstrual cycle-linked condition with both mental and physical symptoms. Most women of fertile age experience cyclical changes but consider them normal and not requiring treatment. Up to 30% of women feel a need for treatment. The aetiology is still unclear, but sex steroids produced by the corpus luteum of the ovary are thought to be symptom provoking, as the cyclicity disappears in anovulatory cycles when a corpus luteum is not formed. Progestogens and progesterone together with estrogen are able to induce similar symptoms as seen in PMS. Symptom severity is sensitive to the dosage of estrogen. The response systems within the brain known to be involved in PMS symptoms are the serotonin and GABA systems. Progesterone metabolites, especially allopregnanolone, are neuroactive, acting via the GABA system in the brain. Allopregnanolone has similar effects as benzodiazepines, barbiturates and alcohol; all these substances are known to induce adverse mood effects at low dosages in humans and animals. SSRIs and substances inhibiting ovulation, such as gonadotrophin-releasing hormone (GnRH) agonists, have proven to be effective treatments. To avoid adverse effects when high dosages of GnRH agonists are used, add-back hormone replacement therapy is recommended. Spironolactone also has a beneficial effect, although not as much as SSRIs and GnRH agonists.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brain Res. 2001 Aug 10;910(1-2):55-66 - PubMed
    1. Neuroendocrinology. 1998 Feb;67(2):126-38 - PubMed
    1. Am J Obstet Gynecol. 1988 Jan;158(1):5-11 - PubMed
    1. Hum Reprod. 1994 Jun;9(6):1058-63 - PubMed
    1. Health Psychol. 2001 Jul;20(4):276-80 - PubMed

Publication types

MeSH terms

LinkOut - more resources